Raleigh, NC, May 11, 2010 – INC Research ®, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, has appointed J. Michael Hamilton, MD as senior medical director in its Oncology practice. Based outside of Washington, DC, Dr. Hamilton’s oncology and drug development expertise supports medical monitoring, team training and brings a consultative approach to the Trusted Process® for oncology related clinical trials.
“We are thrilled to welcome Mike to our oncology team, as his background speaks for itself. In addition, and just as important, Mike shares the same passion and approach for improving oncology patient outcomes through effective clinical trials as the rest of our oncology team,” said Nick Kenny, PhD, executive vice president, Oncology at INC Research.
Dr. Hamilton has more than 25 years of experience in clinical oncology and hematology-oncology drug development. During 17 years at the National Cancer Institute, he oversaw clinical strategy in colorectal cancer and CNS tumors in the Cooperative Group system. In this setting, he also conducted Phase I clinical trials with new agents, including anti-tumor vaccines, and fulfilled duties as chairman of the NCI Institutional Review Board, director of the Oncology Fellowship Training Program, and supervisor of the hematology-oncology research nurses, outpatient clinic, and in-patient oncology unit at the National Naval Medical Center.
Subsequently, for seven years at GlaxoSmithKline (GSK), he was the medical director for the FDA approval and late phase development of BEXXAR and the early development, leading to the FDA approval of Promacta (eltrombopag) as well as the development of other hematology-oncology compounds and vaccines. After leaving GSK, Dr. Hamilton served as the chief medical officer (CMO) at Avalon Pharmaceuticals where he oversaw all clinical strategic planning and development of discovery and clinical projects, as well as evaluation and ranking of licensing opportunities. Dr. Hamilton continues to teach patient care and clinical oncology to NCI Fellows at the National Naval Medical Center in Bethesda, MD.
INC Research has conducted more than 350 Phase I through IV oncology trials with nearly 35,000 patients and 4,000 investigative sites around the globe. The team has investigated nearly 130 new and various anticancer therapies, including the introduction of more than 30 new chemical entities (NCEs) in first-in-man trials. The Oncology practice is dedicated to advancing scientific knowledge and helping patients through focused, thoughtful management of critical oncology trials.
For more information on INC Research’s Oncology practice, click here.
